Delineation of the signaling pathways downstream of GPR68 and RCAN1 uncovers novel therapeutic targets that enhance the sensitivity to lenalidomide, especially in R/R and aggressive myeloid malignancies irrespective of del(5q). The gene discussed is RCAN1; the disease is myeloid neoplasm.